Vahakn B. Shahinian

TL;DR: It is suggested that decreasing rates of diagnosis, changing attitudes, and guidelines calling for reduced prostate-specific antigen screening, not changes in practice patterns among specialists treating diagnosed men, drove the decline in population-based treatment rates.

TL;DR: Urologists are increasingly prescribing oral therapies for metastatic castration-resistant prostate cancer, a disease most commonly treated by medical oncologists, using data from the Centers for Medicare and Medicaid Services and the geographic distribution of those providers.

TL;DR: Instrumental variable analysis appears to provide better control of bias when assessing the effectiveness of primary ADT for prostate cancer, although the results may be more applicable to policy rather than to clinical decisions.

TL;DR: The antiresorptive agents are clearly able to preserve bone mineral density in men on ADT, whereas other approaches have modest to no benefits, emphasizing the importance of restricting the use of ADT to settings in which its benefits are clearly established, in order to limit unnecessary complications.

TL;DR: Healthcare integration was associated with small declines in prostate cancer treatment in newly diagnosed men, but not with potential overtreatment, suggesting integrated care alone may be insufficient to curtail potential overt treatment of prostate cancer.